doi:10.3969/j.issn.1673-8640.2023.10.013

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 10

[1]	SPROSTON N R, ASHWORTH J J. Role of C-reactive protein at sites of inflammation and infection[J]. Front Immunol, 2018, 9:754. DOI PMID
[2]	PEARSON T A, MENSSAH G A, ALEXANDER R W, et al. Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association[J]. Circulation, 2003, 107(3):499-511. DOI URL
[3]	SONG M, DAI S, LI J, et al. Establishment of pediatric reference intervals for complete blood count parameters in capillary blood in Beijing[J]. Int J Lab Hematol, 2021, 43(6):1363-1372. DOI PMID
[4]	RIGBY R A, STASINOPOULOS D M. Generalized additive models for location,scale and shape[J]. Journal of the Royal Statistical Society, 2005, 54(3):507-544.
[5]	ONIS M D, GARZA C, ONYANGO A W, et al. WHO growth standards for infants and young children[J]. Arch Pediatrie, 2008, 16(1):47-53. DOI URL
[6]	SCHLENZ H, INTEMANN T, WOLTERS M, et al. C-reactive protein reference percentiles among pre-adolescent children in Europe based on the IDEFICS study population[J]. I Int J Obes(Lond), 2014, 38(Suppl 2):S26-S31.
[7]	ZHANG S, JIANG C, TU C. Chinese preschool children growth reference standard and related curve:based on GAMLSS approach[J]. Iran J Public Health, 2021, 50(6):1250-1259.
[8]	范晖, 闫银坤, 米杰. 中国3-17岁儿童性别、年龄别和身高别血压参照标准[J]. 中华高血压杂志, 2017, 25(5):428-435.
[9]	RÖDÖÖ P, RIDEFELT P, ALDRIMER M, et al. Population-based pediatric reference intervals for HbA1c,bilirubin,albumin,CRP,myoglobin and serum enzymes[J]. Scand J Clin Lab Invest, 2013, 73(5):361-367. DOI URL
[10]	COLANTONIO D A, KYRIAKOPOULOU L, CHAN M K, et al. Closing the gaps in pediatric laboratory reference intervals:a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children[J]. Clin Chem, 2012, 58(5):854-868. DOI URL

组别	男童					女童
组别	例数（%）	均值/ （mg/L）	标准差/ （mg/L）	偏度	峰度	例数（%）	均值/ （mg/L）	标准差/ （mg/L）	偏度	峰度
<2岁组	66（15.98）	3.94^*	2.72	0.20	-1.30	49（22.69）	2.49	2.18	0.96	0.13
2~<4岁组	111（26.88）	3.25	2.59	0.57	-0.74	65（30.09）	2.85	2.55	0.80	-0.45
4~<6岁组	97（23.49）	3.05	2.60	0.75	-0.47	52（24.07）	3.40	2.36	0.55	-0.36
6~<8岁组	55（13.32）	3.63	2.88	0.38	-1.24	30（13.89）	3.70	3.08	0.48	-1.33
8~<10岁组	39（9.44）	3.03	2.90	0.73	-0.97	15（6.94）	2.87	3.00	1.08	-0.57
10~<12岁组	45（10.90）	3.74	3.20	0.36	-1.60	5（2.31）	3.70	2.44	0.13	0.01

组别	男童					女童
组别	例数（%）	均值/ （mg/L）	标准差/ （mg/L）	偏度	峰度	例数（%）	均值/ （mg/L）	标准差/ （mg/L）	偏度	峰度
<2岁组	66（15.98）	3.94^*	2.72	0.20	-1.30	49（22.69）	2.49	2.18	0.96	0.13
2~<4岁组	111（26.88）	3.25	2.59	0.57	-0.74	65（30.09）	2.85	2.55	0.80	-0.45
4~<6岁组	97（23.49）	3.05	2.60	0.75	-0.47	52（24.07）	3.40	2.36	0.55	-0.36
6~<8岁组	55（13.32）	3.63	2.88	0.38	-1.24	30（13.89）	3.70	3.08	0.48	-1.33
8~<10岁组	39（9.44）	3.03	2.90	0.73	-0.97	15（6.94）	2.87	3.00	1.08	-0.57
10~<12岁组	45（10.90）	3.74	3.20	0.36	-1.60	5（2.31）	3.70	2.44	0.13	0.01

年龄	男童						女童
年龄	P₅₀	P₇₅	P₉₀	P₉₅	P₉₇	P₉₉	P₅₀	P₇₅	P₉₀	P₉₅	P₉₇	P₉₉
<2/岁	3.47	6.00	8.66	10.38	11.54	13.8	2.33	4.05	5.86	7.04	7.83	9.39
2~<4/岁	2.97	5.14	7.41	8.88	9.88	11.82	2.39	4.15	6.00	7.21	8.02	9.62
4~<6/岁	2.78	4.80	6.93	8.30	9.23	11.05	2.60	4.51	6.53	7.84	8.72	10.46
6~<8/岁	2.77	4.79	6.92	8.29	9.21	11.03	3.03	5.26	7.62	9.15	10.18	12.21
8~<10/岁	2.93	5.06	7.30	8.75	9.73	11.64	2.97	5.16	7.46	8.96	9.97	11.96
10~<12/岁	3.13	5.41	7.81	9.36	10.4	12.45	2.50	4.35	6.29	7.56	8.41	10.08

年龄	男童						女童
年龄	P₅₀	P₇₅	P₉₀	P₉₅	P₉₇	P₉₉	P₅₀	P₇₅	P₉₀	P₉₅	P₉₇	P₉₉
<2/岁	3.47	6.00	8.66	10.38	11.54	13.8	2.33	4.05	5.86	7.04	7.83	9.39
2~<4/岁	2.97	5.14	7.41	8.88	9.88	11.82	2.39	4.15	6.00	7.21	8.02	9.62
4~<6/岁	2.78	4.80	6.93	8.30	9.23	11.05	2.60	4.51	6.53	7.84	8.72	10.46
6~<8/岁	2.77	4.79	6.92	8.29	9.21	11.03	3.03	5.26	7.62	9.15	10.18	12.21
8~<10/岁	2.93	5.06	7.30	8.75	9.73	11.64	2.97	5.16	7.46	8.96	9.97	11.96
10~<12/岁	3.13	5.41	7.81	9.36	10.4	12.45	2.50	4.35	6.29	7.56	8.41	10.08

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 10

Related Articles 15

Recommended Articles

Metrics